Open AccessComplementary epitopes and favorable developability of monoclonal anti-LAMP1 antibodies generated using two transgenic animal platforms
Author(s) -
Béatrice Cameron,
Tarik Dabdoubi,
Laurence Berthou-Soulié,
Marie Gagnaire,
Isabelle Arnould,
Anne Sévérac,
F Soubrier,
Jacqueline Morales,
Philip A. Leighton,
William Harriman,
Kathryn H. Ching,
Yasmina Abdiche,
Katarina Radošević,
Thomas Bouquin
Publication year - 2020
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0235815
Subject(s) - monoclonal antibody , immunogenicity , epitope , antibody , transgene , biology , recombinant dna , virology , microbiology and biotechnology , computational biology , immunology , biochemistry , gene
Monoclonal antibodies (mAbs) for therapeutic applications should be as similar to native human antibodies as possible to minimize their immunogenicity in patients. Several transgenic animal platforms are available for the generation of fully human mAbs. Attributes such as specificity, efficacy and Chemistry, Manufacturing and Controls (CMC) developability of antibodies against a specific target are typically established for antibodies obtained from one platform only. In this study, monoclonal antibodies (mAbs) cross-reactive against human and cynomolgus LAMP1 were derived from the human immunoglobulin transgenic TRIANNI mouse and OmniChicken ® platforms and assessed for their specificity, sequence diversity, ability to bind to and internalize into tumor cells, expected immunogenicity and CMC developability. Our results show that the two platforms were complementary at providing a large diversity of mAbs with respect to epitope coverage and antibody sequence diversity. Furthermore, most antibodies originating from either platform exhibited good manufacturability characteristics.